Virtual Workshop featuring presentations & discussions on selected abstracts from the 63rd ASH Annual Meeting

The Post-ASH 2021 iwMPNs Virtual Workshop will be held on 28 January 2022. The program will feature a series of short presentations from invited experts on selected abstracts from the 63rd ASH Annual Meeting with interactive panel discussions after each session.

Apply for registration for iwAL here

This event is for hematologists, researchers, nurses, and allied medical professionals only. We will review your application and confirm your registration on submission. By applying, you confirm that your details are correct and that VJHemOnc can communicate with you regarding this event and relevant updates
Scientific Committee:

Prof. Claire Harrison, London, United Kingdom, Co-chair
Prof. Srdan Verstovsek, Houston, USA, Co-chair
Prof. Ruben Mesa, San Antonio, USA
Dr Naveen Pemmaraju, Houston, USA
Dr Aaron Gerds, Cleveland, USA
Dr Deepti Radia, London, United Kingdom

Agenda (all times EST)

 

12:30 – 13:05 | Session 1: Scientific Advances in the MPN field
Chairs: Claire Harrison & Naveen Pemmaraju

• Single-Cell Multi-Omics Reveals the Genetic, Cellular and Molecular Landscape of TP53 Mutated Leukemic Transformation in MPN: Adam Mead – 003

• Myeloproliferative Neoplasms (MPN) Clonal Evolution Landscape and Its Impact on Patients’ Prognosis: Lin-Pierre Zhao – 317

• A JAK2V617F Variant Allele Frequency Greater Than 50% Identifies Patients with Polycythemia Vera at High Risk for Venous Thrombosis: Alessandro Vannucchi – 237

• Single Cell Mutation Analysis Delineates Clonal Architecture in Leukemic Transformation of Myeloproliferative Neoplasms: Alessandro Vannucchi – 56

Discussion – panellists: Alessandro Vannucchi, Lin-Pierre Zhao, Adam Mead

13:05 – 13:50 | Session 2: Novel Therapies for MF
Chairs: Aaron Gerds & Srdan Verstovsek

• A Phase 1/2 Study of Single Agent Tagraxofusp, a First-in-Class CD123-Targeted Therapy, in Patients with Myelofibrosis That Is Relapsed/Refractory Following JAK Inhibitor Therapy:  Abdulraheem Yacoub – 140

• Pelabresib (CPI-0610) Monotherapy in Patients with Myelofibrosis – Update of Clinical and Translational Data from the Ongoing Manifest Trial: Srdan Verstovsek – 141

• Treatment of Myelofibrosis Patients with the TGF-β 1/3 Inhibitor AVID200 (MPN-RC 118) Induces a Profound Effect on Platelet Production: John Mascarenhas – 142

• Pacritinib – a trio of abstracts 3639, 3640,3649 safety analysis, long term compassionate use data and head to head comparisons with ruxolitinib: Claire Harrison – 3639, 3640,3649

• Potential Disease-Modifying Activity of Navtemadlin (KRT-232), a First-in-Class MDM2 Inhibitor, Correlates with Clinical Benefits in Relapsed/Refractory Myelofibrosis (MF): Pankit Vachani – 3851

Discussion – panellists: Abdulraheem Yacoub, John Mascarenhas, Pankit Vachani, Serge Verstovsek, Claire Harrison

13:50 – 14:30 | Session 3: Therapies For MPN, Mastocytosis, and MLN with FGFR1 rearrangement
Chairs: Deepti Radia & Srdan Verstovsek

• Efficacy of Avapritinib in Patients with Advanced Systemic Mastocytosis: Hematologic and Bone Marrow Responses from the Phase 2 Open-Label, Single-Arm, Pathfinder Study: Jason Gotlib – 2565

• A Phase 2 Study of Bezuclastinib (CGT9486), an Oral, Selective, and Potent KIT D816V Inhibitor, in Adult Patients with Advanced Systemic Mastocytosis (AdvSM):  Jason Gotlib – 3636

• A Phase 2 Study of Pemigatinib (FIGHT-203; INCB054828) in Patients with Myeloid/Lymphoid Neoplasms (MLNs) with Fibroblast Growth Factor Receptor 1 (FGFR1) Rearrangement (MLNFGFR1):  Andreas Reiter – 385

• A Phase 2 Study of the LSD1 Inhibitor Img-7289 (bomedemstat) for the Treatment of Essential Thrombocythemia (ET):  Francesca Palandri – 386

• Rusfertide (PTG-300) Controls Hematocrit Levels and Essentially Eliminates Phlebotomy Requirement in Polycythemia Vera Patients: Ronald Hoffman – 388

• Reduced Intensity Stem Cell Transplantation for Accelerated-Phase Myelofibrosis: Nico Gagelmann – 314

• Efficacy of HMA +/- Venetoclax or Intensive Chemotherapy in Blast-Phase Myeloproliferative: Kristen Petit – 2549

Discussion – panellists: Jason Gotlib, Francesca Palandri, Ronald Hoffman, Andreas Reiter, Nico Gagelmann

14:30 – 15:10 | Session 4: Open Case Studies
Chairs: Aaron Gerds, Naveen Pemmaraju, Deepti Radia

• Adore: A Randomized, Open-Label, Phase 1/2 Open-Platform Study Evaluating Safety and Efficacy of Novel Ruxolitinib Combinations in Patients with Myelofibrosis: Claire Harrison – 1489

• INDEPENDENCE: A Phase 3 Study of Efficacy and Safety of Luspatercept Versus Placebo in Patients with Myeloproliferative Neoplasm-Associated Myelofibrosis on JAK2 Inhibitor Therapy and Requiring Red Blood Cell Transfusions: Ruben Mesa – 1490

• Surpass-ET Trial: A Phase 3, Open-Label, Multicenter, Randomized, Active-Controlled Study to Assess Pharmacokinetics and Compare the Efficacy, Safety, and Tolerability of P1101 Vs Anagrelide As Second Line Therapy for Essential Thrombocythemia: Ruben Mesa –  1491

• A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Add-on Parsaclisib in Patients with Myelofibrosis Who Have Suboptimal Response to Ruxolitinib: Abdulraheem Yacoub – 1502

• A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy (BAT) in Patients with Intermediate-2 (Int-2) or High-Risk Myelofibrosis (MF) Refractory to Janus Kinase Inhibitor (JAKi):  John Mascarenhas – 1503

• A Phase 3 Study of the Hepcidin Mimetic Rusfertide (PTG-300) in Patients with Polycythemia Vera: Srdan Verstovsek– 1504

• A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ruxolitinib Plus Parsaclisib in Patients with JAK- and PI3K-Inhibitor Treatment–Naive Myelofibrosis: Abdulraheem Yacoub – 2579

• A Pilot Study of the Anti-SLAMF7 Monoclonal Antibody, Elotuzumab, in Myelofibrosis: Prithviraj Bose – 3635

Discussion – panellists: Prithviraj Bose, Srdan Verstovsek, Abdulraheem Yacoub, David Ross, John Mascarenas

Apply for registration for iwAL here

This event is for hematologists, researchers, nurses, and allied medical professionals only. We will review your application and confirm your registration on submission. By applying, you confirm that your details are correct and that VJHemOnc can communicate with you regarding this event and relevant updates
The Post-ASH 2021 iwMPNs Virtual Workshop has been supported by:

 

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter